Longeveron (LGVN) Gross Profit (2020 - 2026)

Longeveron's (LGVN) quarterly Gross Profit came in at $264000.0 in Q1 2026, down 4.0% year-on-year from $275000.0 in Q1 2025, and up 2.72% quarter-over-quarter from $257000.0 in Q4 2025.

Longeveron (LGVN) Gross Profit (2020 - 2026) Analysis & Trends

Longeveron's Gross Profit history runs 7 years deep, the most recent figure standing at $264000.0 for Q1 2026.

  • On a quarterly basis, Gross Profit fell 4.0% year-over-year to $264000.0 in Q1 2026; TTM through Mar 2026 was $792000.0, a 56.74% decrease from a year earlier, with the FY2025 full-year figure at $803000.0, down 57.38% from the prior year.
  • Gross Profit grew to $264000.0 in Q1 2026 per LGVN's latest filing, from $257000.0 in the prior quarter.
  • Across five years, Gross Profit topped out at $682000.0 in Q3 2024 and bottomed at -$55000.0 in Q4 2022.
  • The 5-year median for Gross Profit is $160000.0 (2022), against an average of $207941.2.
  • Across the five-year window, Gross Profit plunged 179.71% in 2022 and soared 26600.0% in 2024, its largest moves.
  • Year by year, Gross Profit stood at -$55000.0 in 2022, then soared by 96.36% to -$2000.0 in 2023, then surged by 26600.0% to $530000.0 in 2024, then slumped by 51.51% to $257000.0 in 2025, then advanced by 2.72% to $264000.0 in 2026.
  • Per Business Quant, the three latest LGVN Gross Profit figures stand at $264000.0 (Q1 2026), $257000.0 (Q4 2025), and $125000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Longeveron 3.97 Mn -11.79 Mn 264,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 264,000.00
Mar 31, 2026 264,000.00
Dec 31, 2025 257,000.00
Dec 31, 2025 257,000.00
Sep 30, 2025 125,000.00
Sep 30, 2025 125,000.00
Jun 30, 2025 146,000.00
Jun 30, 2025 146,000.00
Mar 31, 2025 275,000.00
Mar 31, 2025 275,000.00
Dec 31, 2024 530,000.00
Dec 31, 2024 530,000.00
Sep 30, 2024 682,000.00
Sep 30, 2024 682,000.00
Jun 30, 2024 344,000.00
Jun 30, 2024 344,000.00
Mar 31, 2024 329,000.00
Mar 31, 2024 329,000.00
Dec 31, 2023 -2,000.00
Dec 31, 2023 -2,000.00